37 Recruiting Multiple Myeloma Clinical Trials in California
Explore active multiple myeloma research studies enrolling across California. Verify eligibility and contact site coordinators.
📍 Find Near Me by DistanceBrowse by City
Recruiting Multiple Myeloma Studies in California
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
📍 Beverly Hills Cancer Center — Beverly Hills, California
View Study & Checklist ➔A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
📍 Local Institution - 0131 — Los Angeles, California
View Study & Checklist ➔A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
📍 UCLA Medical Center — Los Angeles, California
View Study & Checklist ➔Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
📍 University of California Davis — Davis, California
View Study & Checklist ➔A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
📍 UCSF — San Francisco, California
View Study & Checklist ➔A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
📍 UCSF Fresno — Clovis, California
View Study & Checklist ➔Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
📍 UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
View Study & Checklist ➔A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
📍 University Of California San Diego — San Diego, California
View Study & Checklist ➔A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
📍 City of Hope — Duarte, California
View Study & Checklist ➔A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
📍 City of Hope National Medical Center — Duarte, California
View Study & Checklist ➔A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of California San Francisco (UCSF) - Parnassus Heights /ID# 238680 — San Francisco, California
View Study & Checklist ➔Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
📍 City of Hope — Duarte, California
View Study & Checklist ➔A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
📍 University of California San Francisco — San Francisco, California
View Study & Checklist ➔Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
View Study & Checklist ➔Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
📍 UCI Health - Irvine Infusion Pharmacy ACC — Irvine, California
View Study & Checklist ➔A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
📍 City of Hope National Medical Center /ID# 273132 — Duarte, California
View Study & Checklist ➔A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
📍 University of California San Francisco — San Francisco, California
View Study & Checklist ➔Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
📍 University of Southern California /ID# 272414 — Los Angeles, California
View Study & Checklist ➔A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
📍 Global Oncology, Inc. — Alhambra, California
View Study & Checklist ➔Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
📍 Stanford University — Palo Alto, California
View Study & Checklist ➔AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
📍 Research Site — Duarte, California
View Study & Checklist ➔Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
📍 Beverly Hills Cancer Center /ID# 266921 — Beverly Hills, California
View Study & Checklist ➔A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
📍 UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic — San Francisco, California
View Study & Checklist ➔A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 City of Hope — Duarte, California
View Study & Checklist ➔Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
📍 City of Hope National Medical Center — Duarte, California
View Study & Checklist ➔Delayed Toxicities Post-CAR-T
📍 UCSF Medical Center — San Francisco, California
View Study & Checklist ➔A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
📍 Beverly Hills Cancer Center (BHCC) — Beverly Hills, California
View Study & Checklist ➔A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
📍 Clovis Community Medical Center — Clovis, California
View Study & Checklist ➔Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
📍 University of Calfornia, San Francisco — San Francisco, California
View Study & Checklist ➔A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
📍 Scripps Clinic Torrey Pines — La Jolla, California
View Study & Checklist ➔Elranatamab in Relapsed/Refractory Multiple Myeloma
📍 University of California San Diego — La Jolla, California
View Study & Checklist ➔Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
📍 University of California, San Francisco — San Francisco, California
View Study & Checklist ➔A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
📍 City of Hope National Medical Center /ID# 280273 — Duarte, California
View Study & Checklist ➔A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
📍 University of California Los Angeles (UCLA) — Los Angeles, California
View Study & Checklist ➔A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
📍 GSK Investigational Site — Los Alamitos, California
View Study & Checklist ➔Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
📍 Berenson Cancer Center — West Hollywood, California
View Study & Checklist ➔